Fig. 3From: A new ALK isoform transported by extracellular vesicles confers drug resistance to melanoma cellsThe combination of ALK and PLX4032 inhibitors is efficient in resistant melanoma cells. (a) ALK inhibitors (Crizotinib, Ceritinib and ASP3026) dose-response in resistant A375X1 cells cultured in the absence or presence of 1 μM of PLX4032. (b) PLX4032 dose-response in resistant cells cultured with or without 1 μM of ALK inhibitors. (c) Western blot analysis of resistant A375X1 cells treated with PLX4032 for the indicated time points in the presence of absence of ALK inhibitors. α-Tubulin was used as a loading control and one representative of three biological replicates is shown. (d) Apoptosis assays showing the activity of caspase-3 in resistant and sensitive cells treated either with single inhibitors or with a combination of ALK and BRAF inhibitors, normalised to the untreated control. Error bars represent the standard deviation of three technical replicates of three biological replicates. Statistical significance was determined with a one-way ANOVA coupled with Tukey’s multiple comparison tests. *p < 0.05, **p < 0.01, ***p < 0.001Back to article page